EGFR and non-small cell lung carcinoma: Yang et al. studied the plasma samples from 93 advanced NSCLC patients treated with osimertinib as second-line therapy and found that 1/3 of the patients developed EGFR tertiary mutation (such as EGFRm/T790M/C797S) after osimertinib resistance [52].